Get the Stockscreener App
5.39
2.00%
-0.11
After Hours:
5.39
Aldeyra Therapeutics Inc stock is traded at $5.39, with a volume of 1.20M.
It is down -2.00% in the last 24 hours and down -6.34% over the past month.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.
See More
Previous Close:
$5.50
Open:
$5.45
24h Volume:
1.20M
Relative Volume:
2.34
Market Cap:
$318.50M
Revenue:
-
Net Income/Loss:
$-37.54M
P/E Ratio:
-6.0562
EPS:
-0.89
Net Cash Flow:
$-30.33M
1W Performance:
-3.41%
1M Performance:
-6.34%
6M Performance:
+64.83%
1Y Performance:
-19.31%
1-Day Range:
$5.26
$5.61
1-Week Range:
$5.26
$5.77
52-Week Range:
$1.42
$6.74
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
Name
Aldeyra Therapeutics Inc
Sector
Industry
Phone
781-761-4904
Address
131 HARTWELL AVENUE, LEXINGTON, MA
Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-27-22 | Resumed | H.C. Wainwright | Buy |
| Feb-08-21 | Initiated | H.C. Wainwright | Buy |
| Dec-16-20 | Initiated | Berenberg | Buy |
| Oct-30-20 | Initiated | Jefferies | Buy |
| Oct-16-20 | Initiated | BTIG Research | Buy |
| Sep-22-20 | Initiated | Alliance Global Partners | Buy |
| May-12-20 | Initiated | Oppenheimer | Outperform |
| Dec-04-18 | Initiated | Citigroup | Buy |
| Sep-26-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Sep-13-18 | Initiated | Janney | Buy |
| Jan-26-18 | Initiated | Seaport Global Securities | Buy |
| Sep-26-16 | Initiated | H.C. Wainwright | Buy |
| Jul-01-16 | Initiated | Stifel | Buy |
| Jul-01-15 | Initiated | Canaccord Genuity | Buy |
| Mar-25-15 | Initiated | Chardan Capital Markets | Buy |
| Mar-20-15 | Reiterated | H.C. Wainwright | Buy |
| Nov-18-14 | Initiated | H.C. Wainwright | Buy |
| Jun-19-14 | Initiated | Aegis Capital | Buy |
View All
Aldeyra Therapeutics Inc Stock (ALDX) Latest News
Market Watch Highlights: Aldeyra Therapeutics Inc (ALDX) Ends on an Upturn Note at 5.50 - The Dwinnex
Aldeyra Therapeutics Inc (ALDX) Performance and Fundamentals Dashboard tells a completely different story - SETE News
Perceptive Advisors LLC Acquires 682,265 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - MarketBeat
(ALDX) Trading Signals - Stock Traders Daily
Market Highlights: Aldeyra Therapeutics Inc (ALDX) Ends on a High Note at 5.65 - The Dwinnex
What technical indicators reveal about ALDX stock - US Post News
Bank of New York Mellon Corp Has $648,000 Stock Position in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
Insider Sale Alert: Aldeyra Therapeutics Inc [ALDX] – Is it Time to sell? - Knox Daily
Get in on Aldeyra Therapeutics Inc’s (ALDX) buy-in window today! - SETE News
Federated Hermes Inc. Takes Position in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - MarketBeat
Federated Hermes Inc. Invests $1.76 Million in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
Aldeyra To Make Second Bid For FDA Approval Of Dry Eye Disease Drug - RTTNews
(ALDX) Proactive Strategies - Stock Traders Daily
Los Angeles Capital Management LLC Decreases Stake in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
Oppenheimer Upgrades Aldeyra Therapeutics Inc (ALDX) to an Outperform from a Perform - Knox Daily
PFG Investments LLC Purchases Shares of 396,247 Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - MarketBeat
ALDX Stock Sees Surge of Approximately 20.38% in Last Five Days - Knox Daily
There is no doubt that Aldeyra Therapeutics Inc (ALDX) ticks all the boxes. - SETE News
Metric Deep Dive: Understanding Aldeyra Therapeutics Inc (ALDX) Through its Ratios - The Dwinnex
Aldeyra Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
High Growth Tech Stocks To Watch In The United States - Yahoo Finance
Aldeyra Therapeutics Inc (ALDX) requires closer examination - US Post News
Aldeyra Therapeutics appoints new financial officer - Investing.com India
Aldeyra Therapeutics appoints new financial officer By Investing.com - Investing.com Canada
Aldeyra Therapeutics appoints new financial officer By Investing.com - Investing.com UK
Aldeyra Therapeutics Announces Executive Team Changes - TipRanks
Aldeyra Therapeutics Inc Inc. (ALDX) Price Performance: The Impact of Insider Trading and Institutional Holdings - The InvestChronicle
Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Sees Significant Increase in Short Interest - MarketBeat
Aldeyra Therapeutics Inc (NASDAQ:ALDX) A Bull Case Theory - Insider Monkey
Aldeyra Therapeutics Inc (NASDAQ:ALDX) A Bull Case Theory - Yahoo Finance
Aldeyra Therapeutics Has Data To Trigger AbbVie Partnership (ALDX) - Seeking Alpha
Analysts review Aldeyra Therapeutics Inc’s rating - Knox Daily
Nephrotic Syndrome Drugs Market Growing Rapidly by 2031 - openPR
Hennion & Walsh Asset Management Inc. Boosts Holdings in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
Individual investors who hold 37% of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) gained 14%, institutions profited as well - Simply Wall St
The Attractiveness of Investing In Aldeyra Therapeutics Inc (ALDX) is Growing - Knox Daily
Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Stock Position Raised by Price T Rowe Associates Inc. MD - Defense World
12,265 Shares in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Purchased by Diversified Trust Co - Defense World
Aldeyra Therapeutics executive sells over $75k in stock By Investing.com - Investing.com India
Aldeyra Therapeutics executive sells over $51k in company stock By Investing.com - Investing.com Australia
Aldeyra Therapeutics executive sells over $51k in company stock - Investing.com India
Aldeyra Therapeutics executive sells over $75k in stock - Investing.com
Aldeyra Therapeutics executive sells over $51k in company stock By Investing.com - Investing.com UK
Quarterly Metrics: Quick and Current Ratios for Aldeyra Therapeutics Inc (ALDX) - The Dwinnex
Vanguard Group Inc. Decreases Stake in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
Aldeyra Therapeutics executive sells over $51k in company stock - Investing.com
Riding the Waves: A Guide to Investing in ALDX Stock - The InvestChronicle
Aldeyra (ALDX) Stock Climbs Substantially After Positive Clinical Trial Outcome - Catching News
How did Aldeyra Therapeutics Inc (ALDX) fare last session? - US Post News
Aldeyra Therapeutics (NASDAQ:ALDX) Earns Buy Rating from HC Wainwright - Defense World
Aldeyra Therapeutics Inc [ALDX] Records 200-Day SMA of $3.40 - Knox Daily
Aldeyra Therapeutics Inc Stock (ALDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):